VP
VYNE icon

venBio Partners’s VYNE Therapeutics VYNE Stock Holding History

venBio Partners’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20,299
Closed -$3.92M – 5
2020
Q1 		$3.92M Hold
20,299
– – 3.34% 5
2019
Q4 		$6.78M Hold
20,299
– – 2.91% 5
2019
Q3 		$6.55M Hold
20,299
– – 3.11% 5
2019
Q2 		$8.76M Hold
20,299
– – 3.89% 5
2019
Q1 		$11.5M Hold
20,299
– – 9.29% 3
2018
Q4 		$6.02M Hold
20,299
– – 15.82% 3
2018
Q3 		$14.4M Hold
20,299
– – 25.18% 2
2018
Q2 		$11.9M Hold
20,299
– – 12.24% 3
2018
Q1 		$54.9M Buy
+20,299
New +$49.4M 33.85% 2

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

venBio Partners's VYNE Position: Q2 2020 in Review

venBio Partners sold out of VYNE Therapeutics (VYNE) in Q2 2020, closing a stake of 20,299 shares — an estimated $3.92M sold.

venBio Partners first reported a position in VYNE in Q1 2018 and held it in 9 quarters. The position peaked at $54.9M in Q1 2018. 106 funds tracked by Wall St. Rank hold VYNE as of Q2 2020.

  • venBio Partners reported no remaining VYNE Therapeutics position as of Q2 2020 after selling out during the quarter.
  • venBio Partners sold 20,299 VYNE Therapeutics shares in Q2 2020, an estimated $3.92M.
  • venBio Partners first reported a position in VYNE Therapeutics in Q1 2018 and held it in 9 quarters.
  • venBio Partners's VYNE Therapeutics position peaked at $54.9M in Q1 2018.
  • 106 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2020.

Based on venBio Partners's 13F filing for Q2 2020, filed 14 Aug 2020.